Drugs / XS411CN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07617012 | Jun → Aug 2026 overdue | multiple system atrophy, parkinsonian type | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07080775 | Aug 2025 → Apr 2026 overdue | Parkinson disease | XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XS411CN | “This is a phase I clinical study to evaluate the safety and tolerability of human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell...” NCT07080775 ↗ |
| Modality | Cell therapy | “human allogeneic induced pluripotent stem cell (iPSC)-derived dopaminergic neural progenitor cell injection” NCT07080775 ↗ |
| Route | Other | “via brain stereotactic transplantation” NCT07080775 ↗ |